Possible Antimigraine Mechanisms of Action of the 5HT1F Receptor Agonist LY334370

This study investigated whether the selective 5HT1F receptor agonist LY334370 has other possible antimigraine mechanisms in addition to the proposed inhibition of dural plasma extravasation. LY334370 (up to 10−5 M) had no vasoconstrictor effects on human cerebral arteries in vitro. It had no effect (up to 10 mg kg−1, iv) on neurogenic vasodilation of dural blood vessels produced by electrical stimulation of the dura mater in anesthetized rats. Nor had it any effect (at 3 mg kg−1, iv) on the hyperalgesia produced by injection of carrageenan into the paw of conscious rats or on nociceptive reflex responses in the spinalized, decerebrate rabbit (up to 3 mg kg−1, iv), indicating that it has no general analgesic properties. However, it significantly inhibited activation of second-order neurons in the trigeminal nucleus caudalis produced by electrical stimulation of the dura mater in anesthetised rats at 3 mg kg−1, iv. These results provide evidence to suggest that LY334370 has a central mechanism of action in blocking the transmission of nociceptive impulses within the trigeminal nucleus caudalis and that this may represent a mechanism through which it has its antimigraine effect.

[1]  T. Branchek,et al.  Cloning and Characterization of The Guinea Pig 5-HT1F Receptor Subtype: a Comparison of the Pharmacological Profile to the Human Species Homolog , 1997, Neuropharmacology.

[2]  R. Hargreaves,et al.  Rizatriptan has central antinociceptive effects against durally evoked responses. , 1997, European journal of pharmacology.

[3]  P. Goadsby,et al.  The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats , 1993, Annals of neurology.

[4]  R. Hargreaves,et al.  The non‐peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats , 1993, British journal of pharmacology.

[5]  T. Branchek,et al.  Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. , 1999, European journal of pharmacology.

[6]  L. Edvinsson,et al.  Journal of Cerebral Blood Flow and Metabolism Retrograde Tracing of Nerve Fibers to the Rat Middle Cerebral Artery with True Blue: Colocalization with Different Peptides , 2022 .

[7]  J. Mcculloch,et al.  Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance P , 1985, Neuroscience Letters.

[8]  W. Feniuk,et al.  Mode of action of the anti-migraine drug sumatriptan. , 1991, Trends in pharmacological sciences.

[9]  M. Ferrari,et al.  Clinical and experimental effects of sumatriptan in humans. , 1993, Trends in pharmacological sciences.

[10]  L. Edvinsson,et al.  Neuronal pathways to the rat middle meningeal artery revealed by retrograde tracing and immunocytochemistry. , 1989, Journal of the autonomic nervous system.

[11]  P. Saxena,et al.  Serotonin receptors as cardiovascular targets , 1997 .

[12]  P. Emson,et al.  Coexistence of calcitonin gene-related peptide and substance P-like peptide in single cells of the trigeminal ganglion of the rat: immunohistochemical analysis , 1985, Brain Research.

[13]  J. Olesen,et al.  Role of endothelium and nitric oxide in histamine‐induced responses in human cranial arteries and detection of mRNA encoding H1‐ and H2‐receptors by RT‐PCR , 1997, British journal of pharmacology.

[14]  M. G. Buzzi,et al.  The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater , 1990, British journal of pharmacology.

[15]  J. Pickard,et al.  Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. , 1999, British journal of clinical pharmacology.

[16]  R. Hargreaves,et al.  Sumatriptan Inhibits Neurogenic Vasodilation of Dural Blood Vessels in the Anaesthetized Rat—Intravital Microscope Studies , 1997, Cephalalgia : an international journal of headache.

[17]  Kirk W. Johnson,et al.  5‐HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs , 1997, Neuroreport.

[18]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[19]  R. Hargreaves,et al.  Differential Effects of 5-HT1B/1D Receptor Agonists on Neurogenic Dural Plasma Extravasation and Vasodilation in Anaesthetized Rats , 1997, Neuropharmacology.

[20]  A. Beitz,et al.  An electron microscopic description of glutamate‐like immunoreactive axon terminals in the rat principal sensory and spinal trigeminal nuclei , 1991, The Journal of comparative neurology.

[21]  S. Boyce,et al.  L-745,337: A selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats , 1994, Neuropharmacology.